WHO ICTRP trial
Clinical study of unresectable or metastatic carcinoma of pancreas, biliary…
ChiCTR2000040080 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000040080 |
|---|---|
| Public title | Clinical study of unresectable or metastatic carcinoma of pancreas, biliary tract and periampulle with Camrelizumab combined with low-dose apatinib |
| Scientific title | Clinical study of unresectable or metastatic carcinoma of pancreas, biliary tract and periampulle with Camrelizumab combined with low-dose apatinib |
| Primary sponsor | AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | carcinoma of pancreas, biliary tract and periampulle |
| Interventions | The experimental group:Camrelizumab + Apatinib |
| Registration date | Nov 20, 2020 |
| Target size | The experimental group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: